| Revenue growth | Q2 +12% YoY, +5% QoQ to ₹51.15 Cr |
|---|---|
| Margins | EBITDA margin 5.88%, up 358 bps QoQ; gelatine price hikes expected |
| Demand visibility | Robust demand; Mankind Pharma onboarded, Zydus business expected |
| Management confidence | Demand robust; EBITDA expected in current range |
Growth
Revenue +12% YoY, +5% QoQ to ₹51.15 Cr; H1 revenue +10% to ₹99.86 Cr; PAT loss narrowed 40% YoY.
Outlook
EBITDA to stay in current range; HPMC line conversion adds H2 volumes; COPP filings by March 2027; US FDA audit Q1FY29.
Risks
Freight and container costs, rising coal/oil-linked raw material costs, Fermbox CMO rework delay, API regulatory timelines.
Last quarter's promises, checked
Delivered
- Said Puducherry disruption behind us → Q2FY27 revenue +12% YoY (= BEAT)
Partly delivered
- Guided FY27 restored profitability → Q2 PAT loss ₹4.22 Cr, narrowed 40% YoY (= PARTIAL)
- Guided FY27 revenue ₹274 Cr → H1 ₹99.86 Cr, full year open (= PARTIAL)
- Guided ~₹20 Cr HPMC revenue from H2FY27 → H2 volumes reiterated, US approval pending (= PARTIAL)
Missed
- Guided WHO GMP in Q1FY27, Q2 at latest → still 'audit pending' (= MISS)
- Guided ~₹14 Cr FY27 Fermbox CMO revenue → 'CMO setback', no revenue cited (= MISS)
Investor Presentation filed with BSE, NSE: NATCAPSUQ. Summary written with AI assistance from the document.
Natural Capsules Ltd: key numbers
- Share price
- ₹126.19
- Market cap
- ₹131.4 Cr
- Revenue (annual)
- ₹187.2 Cr
- Net profit (annual)
- ₹-24.66 Cr
- P/E (TTM)
- -8.3×Sector 49.0×
- Promoter holding
- 50.92%+0.00% QoQ
- FII holding
- 0.08%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Natural Capsules Ltd
All →Natural Capsules Earnings Call Transcript: Key Takeaways
Q2 revenue of ₹51.15 Cr (+12% YoY) and a narrower loss, but US capsule demand is absent, HPMC guidance is dropped, and FY27 API revenue guidance is cut to ₹12-15 Cr.
Natural Capsules Results Update
Natural Capsules issued a press release on its Q2 and H1 FY27 results, citing volume growth and API restructuring. Management expects EBITDA to hold steady.
Natural Capsules Results Correction
Natural Capsules Ltd filed a corrigendum fixing a decimal error in six-month segment revenue (Capsules ₹9,050.16 Lakhs, API ₹936.31 Lakhs, total ₹9,986.47 Lakhs). The correction does not change reported results.
Natural Capsules Preferential Issue
Natural Capsules allotted 1,12,500 equity shares to a single investor at Rs.178 each on a preferential basis. The allotment is worth about Rs.2.00 Crore.
- Value
- ₹2.00 Cr
Natural Capsules Legal & Regulatory
Natural Capsules was fined ₹10,000 each by NSE and BSE for short board-meeting notice. The company has paid the fines and cited a late valuation report.
- Value
- ₹0.00 Cr
Natural Capsules Q2 FY27 Results: Net Loss of ₹4.2 Cr, Loss Narrows
Natural Capsules Ltd reported revenue from operations of ₹51.1 Cr (+11.6% YoY) and a net loss of ₹4.2 Cr for Q2 FY27.
- Key figure
- Net loss ₹4.2 Cr